Overcoming Tumor Heterogeneity and Drug Resistance: Rational Design Strategies for Bispecific Aptamers-Special topic on adapter development-Tekbiotech-Yeast and Phage Display CRO, Expert in Nano-body and Antibody Drug Development

Overcoming Tumor Heterogeneity and Drug Resistance: Rational Design Strategies for Bispecific Aptamers

In tumor biology, the survival and proliferation of cancer cells rarely depend on a single signaling pathway. When attacked at a single target, they often escape destruction by activating backup signaling pathways or through interactions with the tumor microenvironment, ultimately leading to drug resistance and relapse. Bispecific aptamers have emerged as a response to this challenge: as a single molecular entity, they can bind two different targets simultaneously. This not only improves specificity and reduces off-target effects, but also actively bridges or blocks interconnected signaling pathways, offering a rational design solution for overcoming drug resistance and tumor heterogeneity.

Core Design Strategies: How to Build a "Two Birds with One Stone" Molecule

Tandem Design

This is the simplest and most straightforward linkage strategy: two aptamer sequences targeting different molecules are joined head-to-tail through a flexible "linker", whose length and sequence can be adjusted. This design preserves the binding capability of each aptamer while adding spatial flexibility and optimizing the cooperativity between the two binding sites.

Branched Design

In this mode, the two aptamers typically form a Y-shaped or T-shaped structure, with different "arms" binding different targets. This architecture allows the two binding domains to work relatively independently with reduced mutual interference, making it particularly suitable for applications that require simultaneous binding of two targets located far apart.

Structure-Sharing Design

This is the most challenging yet most elegant design concept. Through computational prediction and experimental validation, scientists have engineered aptamers that can switch conformation depending on the environment or binding state — that is, a single molecule can recognize two different targets through distinct three-dimensional structures.

Modular Design

In this approach, the aptamer is divided into core functional modules — such as a targeting module, a linker module, and a functional output module — which are then combined through standardized interfaces. This "plug-and-play" concept greatly improves development efficiency and enables personalized design.

Key Technological Breakthroughs: From Theory to Reality

Balancing Affinity and Specificity

Bispecific design must not compromise the binding performance of each individual aptamer. Through "affinity maturation" — systematic mutation and screening — TekBiotech optimizes the performance of both binding sites, ensuring high affinity and high specificity toward both targets simultaneously.

Linker Engineering

The sequence connecting two aptamers is not a randomly designed "rope" but a finely tuned, critical element. Its length, rigidity/flexibility, and chemical properties must be carefully considered, as they directly influence bispecific functionality.

Chemical Modification for Enhanced Stability

Natural nucleic acids are prone to degradation. By introducing chemically modified nucleotides (e.g., 2'-fluoro and 2'-O-methyl modifications), TekBiotech can significantly enhance the serum stability of bispecific aptamers and prolong their in vivo half-life, laying the foundation for clinical applications.

Artificial Intelligence

With advances in artificial intelligence and molecular simulation, computers can predict the binding capacity and structural stability of thousands of candidate designs before experiments begin, greatly accelerating the discovery and optimization of lead molecules.

Development Workflow

Target Pairing and Mechanism Validation

Based on prior research data and disease biology, two targets with synergistic or complementary functions are predicted and selected; the rationale for simultaneous intervention is then verified experimentally.

Lead Screening and Optimization

Aptamers specific to individual targets are first isolated by SELEX technology, then converted into bispecific formats through rational design or iterative screening, followed by multiple rounds of optimization.

In Vitro Functional Validation

Once a bispecific aptamer is identified, its functions — such as simultaneous binding, signaling pathway inhibition, and cytotoxicity — must be validated in cell models and compared with monospecific aptamers.

In Vivo Efficacy and Safety Evaluation

Beyond in vitro validation, therapeutic efficacy, pharmacokinetics, and preliminary safety must be evaluated in animal disease models — an essential stage before clinical translation.

Figure 1 Bispecific aptamer targeting tumor cells via cytotoxic T cells ^[2]

Figure 2 Circular DNA aptamers for diagnostic and therapeutic applications in multiple diseases^[3]

As an innovative company deeply engaged in the frontiers of molecular diagnostics and nucleic acid technology, TekBiotech is committed to translating cutting-edge scientific discoveries into clinically valuable solutions. We focus on the development and application of nucleic acid aptamers, with a full-chain technology platform that spans high-throughput screening, rational design, engineering optimization, and industrial translation.

References

[1] Yoda Y, Potaptschuk E, Ishimori N, et al. Linker Length Optimization of Bispecific DNA Aptamer-Based HER2 Targeting Lysosome-Targeting Chimera (HER2-LYTAC). Chem Pharm Bull (Tokyo). 2025;73(11):1084-1090.

[2] Sun Y, Mo L, Yu D, et al. Bispecific Aptamer-Based Recognition-then-Conjugation Strategy for PD1/PDL1 Axis Blockade and Enhanced Immunotherapy. ACS Nano. 2022;16(12):21129-21138.

[3] Shen T, Zhang Y, Mei L, Zhang XB, Zhu G. Single-stranded circular DNA theranostics. Theranostics. 2022 Jan 1;12(1):35-47. doi: 10.7150/thno.66466.

Previous:Stop Screening Aptamers the Old Way: The Decisive Advantage of Magnetic-Bead SELEX Next:None!